HIV and Drug-Resistant Subtypes: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Bianca Maria Nastri
,
Pasquale Pagliano
,
Carla Zannella
,
Veronica Folliero
,
Alfonso Masullo
,
Luca Rinaldi
,
Massimiliano Galdiero
,
Gianluigi Franci

Acquired Immunodeficiency Syndrome (AIDS) is a human viral infectious disease caused by the positive-sense single-stranded (ss) RNA Human Immunodeficiency Virus (HIV) (Retroviridae family, Ortervirales order). HIV-1 can be distinguished into various worldwide spread groups and subtypes. HIV-2 also causes human immunodeficiency, which develops slowly and tends to be less aggressive. HIV-2 only partially homologates to HIV-1 despite the similar derivation. Antiretroviral therapy (ART) is the treatment approved to control HIV infection, based on multiple antiretroviral drugs that belong to different classes: (i) NNRTIs, (ii) NRTIs, (iii) PIs, (iv) INSTIs, and (v) entry inhibitors. These drugs, acting on different stages of the HIV life cycle, decrease the patient’s total burden of HIV, maintain the function of the immune system, and prevent opportunistic infections.

  • HIV
  • ART
  • drug resistance
  • retrovirus
  • NNRTIs
  • NRTIs
  • PIs
  • INSTIs

1. Introduction: HIV and Its Distribution

AIDS is a global pandemic that currently affects approximately 38 million people worldwide. It is caused by two different lentiviruses, HIV-1 and HIV-2, that derived from multiple cross-species transmissions of the simian immunodeficiency virus until they affected humans [1].
The first isolation of the main agent of AIDS, HIV, was reported in 1983 by Robert Gallo [2] and Luc Montagnier [3], but several studies have documented that the HIV-1 virus was already present in Africa during the 1950s and America during the 1970s, and it spread all over the world in the following years with tens of millions of cases [4].
Two years later, in 1985, HIV-2 was identified as partially responsible for the AIDS pandemic but causing a milder form of immunodeficiency; data about HIV-2 are still limited, and only a few subtypes have been described.
According to the International Committee for the Taxonomy of Viruses (ICTV), HIV belongs to the Retroviridae family, Orthoretrovirinae subfamily, and Lentivirus genus (Figure 1).
Figure 1. Schematic representation of HIV current classification.
Based on different genome sequences risen from an independent cross-species transmission event, the researchers can distinguish HIV-1 groups M (major), O (outlier), N (non-M, non-O), and P.
Group M is the most widespread and includes nine subtypes: A, B, C, D, F, G, H, J, and K. The genetic distance between the subtypes is lower than the one across the groups [5][6][7][8][9].
Moreover, 19 circulating recombinant forms (CRFs) have been identified, including some that play important roles in the epidemic trend [8].
A recombinant is a genetic sequence that carries regions from two genetically distinct parental strains. It depends on the combination of viral genomes of different subtypes affecting the same cell. This leads to multiple changes in its genome, which results in regions from each different subtype [9][10]. The recombination phenomenon increases overall, i.e., the genetic complexity of viral populations more than just the accumulation of site mutations, allowing viral diversification to evade the host immune system and antiretroviral treatment [9].
In addition, the different subtypes have distinct global distribution patterns [5][11].
Therefore, it is clear how the genetic variability of HIV-1 can play a crucial role in its pathogenesis, transmission, diagnosis, treatment, and vaccine development, as well as in HIV drug resistance (HIVdr); for example, group O viruses are known to be naturally resistant to non-nucleoside reverse-transcriptase inhibitors, and M subtypes have all similar susceptibilities to some antiretroviral drugs in use [12][13].
There is a well-defined geographical distribution throughout the world of genetically distinct viruses. In particular, subtype B has become prevalent in almost all parts of Europe, Australia, and North America; subtype C has been mostly found in India and Brazil, as well as South and East Africa; subtype E is common in Thailand; and subtype F has been reported in Romania, Brazil, and Russia [5][14][15]. A large variety of subtypes, such as those of group M, has been reported in Africa, especially in the western central part. Instead, HIV viruses belonging to groups N, O, and P have not spread widely [5]. In addition, HIV-2 cases have been reported especially in Western Africa, whereas only a few have been reported in Europe (Portugal and France), India, and the United States of America [16]. The HIV-2 groups have derived from independent transmissions from sooty mangabeys (Cercocebus atys) to humans. HIV-2 strains are classified into eight groups, named A to H, but only groups A and B can cause epidemics. Isolates from group A are responsible for most of the HIV-2 infections worldwide (especially in Guinea-Bissau), while isolates from group B have been found in Ivory Coast and Ghana. More than one recombinant form, containing sequences of groups A and B, has been identified in Japan, Cameroon, and Ivory Coast. These observations differ largely from those of the other groups since infection with groups C to G has been found in few individuals and rarely leads to immune suppression. Coinfections of HIV-1 and HIV-2 are not as common in West Africa, where they represent 0.3–1% of all HIV-infected patients [17].

2. HIV Diagnosis and Clinical Course

Since HIV was determined to be the pathogen causing AIDS, important improvements have been made to its detection and characterization [18]. However, much depends on the time after the exposure, which leads to infection, since there is a high probability that, during this time, there are no diagnostic tests capable of detecting HIV [19]. In general, HIV RNA is the first marker of infection, which appears to be detectable within 12 days, then reaches its peak around the 20th or 30th day post-infection; meanwhile, on the 15th day, the capsid protein p24 also reaches detectable levels [19].
The first HIV diagnostic test was approved by the US Food and Drug Administration (FDA) in 1985. Today, there are several diagnostic tests, but only the serological and molecular methods remain the gold standard for diagnosing and monitoring HIV infection. In particular, the serological test is used to detect HIV-specific antigens and antibodies, while the molecular assay monitors antiretroviral success and drug resistance [18].
The serological methods consist of using enzyme immunoassays to detect HIV antigens and antibodies, whereas molecular methods consist of amplifying viral RNA in vitro by PCR. Additionally, testing algorithms associated with the techniques used need to be improved for newer detection assays [20] since they can potentially decrease the total number of tests performed and reduce the time between the test and the initiation of treatment [21].
Recent studies highlight the importance of starting an early ART once HIV has been diagnosed [22]. Despite this, because of reasons still unknown but possibly associated with immune and genetic factors, some rare individuals do not need antiretroviral therapy thanks to a spontaneous control of viremia (SCV) [23].
In most cases, instead, HIV infections are treated with ART that, in most of the patients, leads to an acceptable virological suppression if started before any compromise of immune functions [24][25].
Of course, being able to detect HIV early remains the most important element to reduce disease advancement since diagnosis is followed by antiretroviral therapy that increases patient life expectancy and reduces the possibilities of transmission.

3. Treatment

Before the discovery of antiretroviral therapy (ART), HIV/AIDS patients were initially treated with only one or two antiretroviral drugs, which belonged to the class of nucleotide analogs, whose abilities to reduce viral load were very low and hampered by the rapid insurgence of resistance and, consequently, were not able to modify the course of the disease. Approximately 23 years ago, ART, which is based on the combination of different classes of antiretroviral drugs, was developed. This treatment has significantly prolonged survival in patients with AIDS (about 7 to 10 years of survival or longer). The first drug to treat HIV/AIDS approved by the US Food and Drug Administration was zidovudine, a nucleoside reverse-transcriptase inhibitor (NRTI), in 1987, but studies highlighting the effectiveness of combined administration of two drugs NRTI were already released at the beginning of 1990 [26][27][28].
ART can include a combination of nucleoside reverse-transcriptase inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry inhibitors.
Since these drugs belong to different classes, they have different mechanisms of action by which they interfere with a unique step in the life cycle of the virus. Generally, two NRTIs are used in association with another class, such as PI or INSTI, but current data highlight that a simplified two-drug treatment can be equally effective [29]. All these treatments can be modified based on toxicity and induced resistance.
NNRTIs and NRTIs inhibit the polymerase activities of HIV-1 reverse transcriptase (RT), which plays a pivotal role in the HIV life cycle. Reverse transcriptase (RT) is essential for the life cycle of HIV because it converts ingle-stranded genomic RNA into double-stranded DNA, which is subsequently integrated into the host chromosome and passed on to all progeny cells [30].
For that reason, HIV RT has been an ideal target for antiretroviral agents. NRTI drugs approved and used in ART are abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zidovudine, while NNRTI drugs are doravirin, delavirdine, efavirenz, etravirine, nevirapine, and rilpivirine. Many of these drugs are not suggested by current guidelines, owing to several considerations regarding their toxicity or antiviral effects.
Protease inhibitors (PIs) are a major class of drugs effective in treating HIV infection/AIDS because of their high effectiveness in inhibiting HIV replication and their relatively low resistance rate. In the past several years, a variety of protease inhibitors have been found [31]. As expected, these drugs interact with HIV-1 protease, which is responsible for the production of all viral enzymes and structural proteins necessary to produce mature, virulent virions, starting from long polypeptide chains, which are cut to obtain single proteins [32][33].
Therefore, the inhibition of the protease activity effectively interferes with a vital stage in the HIV life cycle [34]. PI drugs include atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, and tipranavir; presently, darunavir is the most frequently used.
The integrase (IN) is an enzyme that HIV uses to insert its viral DNA (vDNA) into the DNA of the host cell through two catalytic actions: 3′ processing and strand transfer.
Although the integrase strand transfer inhibitor (INSTI) antiretroviral drugs are the latest class of agents approved [34][35], they have a key role in the treatment of an HIV-positive individual by inhibiting the strand transfer step made by INs through competitive binding to the enzyme’s active site. Then, INSTIs stop IN action also by chelating the divalent cation (Mg2+ or Mn2+) that is required for its enzymatic activity [36].
There are currently four INSTIs approved for the treatment of HIV infection: raltegravir, elvitegravir, bictegravir, and dolutegravir [37].
Finally, entry inhibitors prevent the virus from entering the cell and include CCR5 antagonist and entry inhibitor of gp41. HIV-1 uses various membrane proteins as a receptor to bind the plasma membrane, such as CCR5 [38][39], or uses gp41, a glycoprotein that physically brings the viral envelope closer to that of the cell membrane, allowing their fusion. Maraviroc binds CCR5, while enfuvirtide binds gp41 [40], preventing the virus’s cell binding or induced membrane fusion and, consequently, its entry into the cell.
Other noteworthy and recent drug classes are capsid inhibitors and NNRTIs.
Lenacapavir represents a new class of drugs called capsid inhibitors [41], approved in December 2022 for the first time by the FDA. Its mechanism of action is inhibiting the disassembly of the capsid shell, a step essential for viral replication. It is used in association with other drugs.
NNRTIs, such as islatravir, which is still in phase 3 clinical trial, inhibit reverse transcription via multiple mechanisms, which can confer a unique mutant susceptibility profile [42].
The treatment for HIV-2 is not the same as the one for HIV-1; in fact, drugs used to treat HIV-2 are NNRTIs and entry inhibitors, while some PIs have weak or no inhibitory activity against HIV-2 [17].
Some people receiving ART have shown severe side effects, such as diarrhea, headache, fatigue, rash, or, worse, treatment failure. Nevertheless, ART has been revealed to be really successful and has allowed the majority of infected people to conduct their normal lives.
The emergence of HIV drug-resistant subtypes, especially caused by the rapid and error-prone replication of the virus, is increasing [30].
Moreover, along with a growing number of drug-resistant strains, ART has led to an ever-growing pool of individuals who can transmit drug-resistant strains of HIV-1 [43][44].

4. Drug Resistance Mechanism

HIV-1 virus has a high mutation rate, accumulating nearly one nucleotide mutation per replication cycle. That is the main reason why there is a considerable HIV-1 variation in patients [45][46].
Since people are usually infected with only a single or a few original clones [47], an exponential number of virions are likely produced each day in untreated individuals, resulting in innumerable variants of the virus. The high HIV-1 recombination rate, due to different variants infecting the same cell, together with its capacity of reactivation in infected cells, increases the complexity of this virus [48][49]. As a matter of fact, it is possible to find a wide spectrum of virus variants infecting the same patient. Unfortunately, most of the time, these variants gain new mechanisms to evade the immune system of the host [50].
People harboring HIV-resistant strains can be divided into two categories: people on ART that acquire HIV drug resistance (ADR) and people who become infected with HIV-resistant strains.
Among people receiving ART, resistance can frequently develop, prompted by suboptimal drug treatment, which can lead to the selection of drug-resistant viruses [46]. When virus replication occurs in the presence of suboptimal concentrations of the drug, drug-resistant viruses are selected, and the replication of drug-resistant viruses in the presence of the drug can further increase the virus’ mutation rate [46].
Other than acquired drug resistance and transmitted resistance, naturally drug-resistant viruses are extremely rare when the viruses are not subjected to selective drug pressure, even more in untreated patients. HIV-1 genetic variability is ensued by the HIV-1 reverse transcriptase (RT) processing errors by recombination when more than one viral variant infects the same cell and by the accumulation of proviral variants during the course of infection [45][49][51][52]. Although most HIV-1 infections are initiated by a single viral variant [39], innumerable variants related to the initially transmitted virus emerge within weeks following infection [51][53].
There are often high levels of cross-resistance within each drug class. Most drug resistance mutations in a specific antiretroviral class decrease susceptibility to one or more antiretroviral drugs of the same class [54]. In contrast, viruses with high levels of drug resistance in one specific antiretroviral class are generally susceptible to drugs that belong to another class. However, there are few cases of cross-resistance between drug classes. Recently, Sun et al. demonstrated the prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART [55]. Doravirine resistance was highly associated with efavirenz and nevirapine resistance and moderately with etravirine and rilpivirine resistance.
Several studies have recently shown an increase in primary resistance rates in various geographic areas [56][57], and a genotypic resistance test is now recommended before the initiation of ART in patients with HIV infection.

5. NRTI Drug Resistance

Nucleoside reverse-transcriptase inhibitors (NRTIs) form the backbone of ART [58].
NRTI drug resistance works in two different biochemical ways. The first mechanism relates to the RT enzyme’s ability to avoid the binding of the NRTI, while retaining the ability to recognize the natural dNTP substrates during polymerization. The second mechanism, instead, relates to the promotion of the hydrolytic removal of the chain terminating NRTI, continuing DNA synthesis [54].
Therefore, HIV has two major routes to escape nucleoside and nucleotide reverse-transcriptase inhibitor class drug selection pressure. One path is through the selection of thymidine analog mutations (TAMs; M41L, D67N, K70R, L210W, T215F/Y, and K219Q = E), which act to increase excision of NRTIs. Interestingly, the TAM pathway 1, which includes mutations at codons 41, 210, and 215, was prevalent among subtype B viruses, whereas mutations at codons 67, 70, and 219 were the most present among subtype C and F viruses. These mutations can be selected either by zidovudine (ZDV) or by stavudine and confer resistance to these drugs [30][59].

6. NNRTIs Drugs Resistance

NNRTIs have a relatively low genetic barrier to resistance. In general, NNRTIs interact with a hydrophobic pocket within the HIV-1 reverse-transcriptase enzyme. Almost all NNRTI-resistance mutations are located in the RT domain hosting this binding pocket [60]. Since the NNRTI-resistance mutation reduces susceptibility to two or more NNRTIs and there are multiple independent NNRTI-resistant lineages, because of the low genetic barrier, there is a high level of cross-resistance inside this drug’s class [54][61][62][63].
As previously described, there is a significant difference between B and non-B subtype viruses. Moreover, non-B subtype viruses were found to have more resistance-associated mutations than B subtype viruses. This difference is mainly due to the widespread mutation E138A, which is twice as common among non-B subtype viruses than B subtype viruses [64].
However, the most common NNRTI mutations are L100I, K101E/P, K103N/S, V106A/M, Y181C/I/V, Y188C/H/L, G190A/S/E, and M230L. K103N is the most frequent NNRT-associated mutation. Each of these mutations, except for L100I, causes intermediate- or high-level phenotypic resistance to nevirapine and, with the exception of Y181C/I/V, efavirenz [65]. It has also been observed that they all cause phenotypic etravirine and rilpivirine resistance except for K103N/S, V106A/M, Y188C/H/L, and G190A/S/E64.
The NNRTI-resistance mutation V106M occurs more often in subtype C viruses from patients treated with nevirapine or efavirenz because V106M requires a single base-pair change in subtype C viruses—GTG (V) => ATG (M)—but a two base-pair change in all other subtypes—GTA (V) => ATG (M) [66].

7. PIs Drugs Resistance

PIs have high genetic barriers to resistance; they act as competitive inhibitors in the active site of HIV-1 protease that usually prevents the enzyme from processing the Gag and Gag/Pol polyprotein precursors necessary for viral maturation [67].
In subtype B viruses, resistance mutations at codons 33, 34, 58, 63, 73, 71, 77, and 84 are more common than in subtype F or C viruses, whereas those at codons 20, 36, and 89 are less common. In subtype F viruses, resistance mutations are more common at codons 10, 20, 35, 36, 48, 74, 57, 82, and 89, whereas they are less common at codons 47 and 93. In subtype C viruses, the frequency of resistance mutations is higher at codons 20, 36, 89, and 93 and lower at codons 10, 30, 43, 46, and 74 [68].
PI-resistance mutations are different: there are major ones and accessory ones, which both act by reducing susceptibility to one or more PIs. The accessory PI-resistance mutations, however, act in combination with the major PI-resistance mutations [54].

8. INSTIs Drugs Resistance

INSTIs block the action of the integrase viral enzyme (responsible for the insertion of the HIV-1 genome into the host DNA) by impeding the correct positioning of viral DNA at the active site of the enzyme and by binding to the catalytic metal cations inside the retroviral IN active site [54]. Raltegravir resistance occurs by three main, occasionally overlapping, mutational pathways: N155H ± E92Q; Q148H/R/K ± G140S/A; Y143C/R [69][70]. Each of these pairs of mutations is often accompanied by other accessory mutations [69]. N155H, Q148R, Y143R, and other mutations have been shown to reduce raltegravir susceptibility. It is very important to consider that except for Y143C/R, most raltegravir-resistance mutations confer cross-resistance to elvitegravir.
Likewise, most elvitegravir-resistance mutations are the cause of raltegravir cross-resistance. Dolutegravir requires a Q148 mutation in combination with E138 ± G140 since it has a higher genetic barrier to resistance than raltegravir and elvitegravir, requiring a Q148 mutation in combination with E138 ± G140 [71]. However, there are other mutations, including N155H in combination with Q148, that appear to increase the risk of developing resistance to dolutegravir.
The fact that a single mutation can reduce raltegravir (and elvitegravir) susceptibility more than 10-fold suggests that these inhibitors have a low genetic barrier to resistance [72][73].
Significant variability in INSTI-associated mutations can influence integrase activity and viral resistance among HIV-1 subtypes [74].

9. Entry Inhibitor Drugs Resistance

9.1. Chemokine Receptor 5 (CCR5) Antagonists

The small-molecule inhibitor maraviroc allosterically inhibits the binding of HIV-1 gp120 to the host CCR5 (R5) co-receptor. Its use is limited to the early phases of HIV infection because CCR5 tropic virus prevalence is very low in the advanced phase of the infection. Mutations seen in patients enrolled in the MOTIVATE trials include G11S + I26V, S18G + A22T, A19S + I26V, I20F + A25D + I26V, and I20F + Y21I in the V3 region. Mutation-conferring resistance to maraviroc affects the V3 loop region and involves mutations that result in increased affinity of gp120 to MVC-bound CCR5, enabling gp120 binding to CCR5 despite conformational changes from MVC binding [75]. Studies on maraviroc resistance patterns are limited [75][76].

9.2. Entry Inhibitor of gp41

Enfuvirtide, the only approved entry inhibitor, binds to gp41, preventing the creation of the entry pore for the capsid of the virus and keeping it out of the cell [77].
Enfuvirtide has a low genetic barrier [78][79]. Mutations that confer enfuvirtide resistance are localized in its binding site, gp41, in codons 36–45 [80][81][82]. In particular, when only one single mutation affects the site of the enfuvirtide, susceptibility is reduced by about 10-fold, while two mutations lead to a reduction of about 100-fold. The most common enfuvirtide mutations are G36DEV, V38EA, Q40H, N42T, and N43D [71]. However, in a recent study, various polymorphisms were observed in the envelope gp41 region. The major polymorphisms were R46K/M/Q, E137K, and S138A. R46K/M/Q and S138A were predominant in subtype CRF07_BC, and E137K was prevalent in subtype B [83].

10. Conclusions

HIV drug resistance is present all over the world. Approximately 38 million people across the globe live with HIV/AIDS, and of these, 36.2 million are adults, and 1.8 million are children (<15 years old). The different available studies concerning the emergence of HIV drug resistance are still in their infancy but pave the way to help in understanding the possible future steps to follow. The work tried to highlight the large number of mutations present globally and underline that many drugs previously administered as part of ART during recent years have lost their efficacy, owing to viral resistance development, prompting new studies in this field to identify new drugs using other mechanisms to inhibit HIV replication.
ART has been shown to reduce HIV mortality, morbidity, and transmission. However, the presence of HIV subtypes with increasing drug resistance can compromise the effectiveness of antiretroviral drugs [71]. The different subtypes of HIV-1 and HIV-2 predominate in certain geographic areas, but their distribution is becoming increasingly heterogeneous as the pandemic progresses. As shown above, certain subtypes, in particular the resistant ones, may be associated with an increased risk of transmission and a faster progression to the development of AIDS.
The rise in HIV drug resistance is one of the greatest threats to global health that can result in millions of deaths. Diagnostic tools such as resistance testing should be considered an integral part of the plan to address this problem. Nevertheless, it is important to remember the limits of these tests since they only report mutations already known to be associated with drug resistance, while they are less interpretable when compared to new drugs or newer mutations. Plus, the interpretation of their results requires a wide expert panel. However, such testing, based on NGS sequencing, can be helpful in estimating the intrinsic replication competence of the virus [84], but resistance testing is currently only recommended for drug-experienced patients for whom therapy is not successful. Resistance testing should, instead, be applied to treatment-naïve patients to find any mutation resistance before beginning the treatment.
Although great progress has been made in monitoring population-level emergence and transmission of HIV drug resistance mutations, the mutated and resistant strains that reemerge under drug-induced selective pressure need to be effectively detected and preferentially extinguished to prevent the development of AIDS.

This entry is adapted from the peer-reviewed paper 10.3390/microorganisms11010221

References

  1. Bbosa, N.; Kaleebu, P.; Ssemwanga, D. HIV Subtype Diversity Worldwide. Curr. Opin. HIV AIDS 2019, 14, 153–160.
  2. Gallo, R.C.; Montagnier, L. The Discovery of HIV as the Cause of AIDS. N. Engl. J. Med. 2003, 349, 2283–2285.
  3. Montagnier, L. 25 Years after HIV Discovery: Prospects for Cure and Vaccine. Virology 2010, 397, 248–254.
  4. Vahlne, A. A Historical Reflection on the Discovery of Human Retroviruses. Retrovirology 2009, 6, 40.
  5. Hemelaar, J.; Gouws, E.; Ghys, P.D.; Osmanov, S. Global and Regional Distribution of HIV-1 Genetic Subtypes and Recombinants in 2004. AIDS 2006, 20, W13–W23.
  6. Sharp, P.M.; Hahn, B.H. Origins of HIV and the AIDS Pandemic. Cold Spring Harb. Perspect. Med. 2011, 1, a006841.
  7. Vidal, N.; Peeters, M.; Mulanga-Kabeya, C.; Nzilambi, N.; Robertson, D.; Ilunga, W.; Sema, H.; Tshimanga, K.; Bongo, B.; Delaporte, E. Unprecedented Degree of Human Immunodeficiency Virus Type 1 (HIV-1) Group M Genetic Diversity in the Democratic Republic of Congo Suggests That the HIV-1 Pandemic Originated in Central Africa. J. Virol. 2000, 74, 10498–10507.
  8. Casado, G.; Thomson, M.M.; Sierra, M.; Nájera, R. Identification of a Novel HIV-1 Circulating ADG Intersubtype Recombinant Form (CRF19_cpx) in Cuba. J. Acquir. Immune Defic. Syndr. 2005, 40, 532–537.
  9. Ng, K.T.; Ong, L.Y.; Takebe, Y.; Kamarulzaman, A.; Tee, K.K. Genome Sequence of a Novel HIV-1 Circulating Recombinant Form 54_01B from Malaysia. J. Virol. 2012, 86, 11405–11406.
  10. Song, H.; Giorgi, E.E.; Ganusov, V.V.; Cai, F.; Athreya, G.; Yoon, H.; Carja, O.; Hora, B.; Hraber, P.; Romero-Severson, E.; et al. Tracking HIV-1 Recombination to Resolve Its Contribution to HIV-1 Evolution in Natural Infection. Nat. Commun. 2018, 9, 1928.
  11. Osmanov, S.; Pattou, C.; Walker, N.; Schwardländer, B.; Esparza, J. WHO-UNAIDS Network for HIV Isolation and Characterization Estimated Global Distribution and Regional Spread of HIV-1 Genetic Subtypes in the Year 2000. J. Acquir. Immune Defic. Syndr. 2002, 29, 184–190.
  12. Hanna, G.J.; Balaguera, H.U.; Freedberg, K.A.; Werner, B.G.; Steger Craven, K.A.; Craven, D.E.; D’Aquila, R.T. Drug-Selected Resistance Mutations and Non-B Subtypes in Antiretroviral-Naive Adults with Established Human Immunodeficiency Virus Infection. J. Infect. Dis. 2003, 188, 986–991.
  13. Rhee, S.-Y.; Shafer, R.W. Geographically-Stratified HIV-1 Group M Pol Subtype and Circulating Recombinant Form Sequences. Sci. Data 2018, 5, 180148.
  14. Gartner, M.J.; Roche, M.; Churchill, M.J.; Gorry, P.R.; Flynn, J.K. Understanding the Mechanisms Driving the Spread of Subtype C HIV-1. EBioMedicine 2020, 53, 102682.
  15. Khan, S.; Zahid, M.; Qureshi, M.A.; Mughal, M.N.; Ujjan, I.D. HIV-1 Genetic Diversity, Geographical Linkages and Antiretroviral Drug Resistance among Individuals from Pakistan. Arch. Virol. 2018, 163, 33–40.
  16. Korber, B.; Gaschen, B.; Yusim, K.; Thakallapally, R.; Kesmir, C.; Detours, V. Evolutionary and Immunological Implications of Contemporary HIV-1 Variation. Br. Med. Bull. 2001, 58, 19–42.
  17. Menéndez-Arias, L.; Alvarez, M. Antiretroviral Therapy and Drug Resistance in Human Immunodeficiency Virus Type 2 Infection. Antivir. Res. 2014, 102, 70–86.
  18. Lu, H.; Tang, Y.-W. Myths in the Laboratory Diagnosis of HIV Infection. Emerg. Microbes Infect. 2019, 8, 1240–1242.
  19. Hurt, C.B.; Nelson, J.A.E.; Hightow-Weidman, L.B.; Miller, W.C. Selecting an HIV Test: A Narrative Review for Clinicians and Researchers. Sex. Transm. Dis. 2017, 44, 739–746.
  20. Alexander, T.S. Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution. Clin. Vaccine Immunol. 2016, 23, 249–253.
  21. Pitasi, M.A.; Patel, S.N.; Wesolowski, L.G.; Masciotra, S.; Luo, W.; Owen, S.M.; Delaney, K.P. Performance of an Alternative Laboratory-Based HIV Diagnostic Testing Algorithm Using HIV-1 RNA Viral Load. Sex. Transm. Dis. 2020, 47, S18–S25.
  22. Robertson, M.M.; Braunstein, S.L.; Hoover, D.R.; Li, S.; Nash, D. Timeliness of Human Immunodeficiency Virus Diagnosis and Antiretroviral Treatment Initiation in the Era of Universal Testing and Treatment. J. Infect. Dis. 2019, 220, 648–656.
  23. Yang, O.O.; Cumberland, W.G.; Escobar, R.; Liao, D.; Chew, K.W. Demographics and Natural History of HIV-1-Infected Spontaneous Controllers of Viremia. AIDS 2017, 31, 1091–1098.
  24. Platten, M.; Linnemann, R.; Kümmerle, T.; Jung, N.; Wyen, C.; Ehren, K.; Gravemann, S.; Gillor, D.; Cornely, O.A.; Fischer, J.; et al. Clinical Course and Quality of Care in ART-Naïve Patients Newly Presenting in a HIV Outpatient Clinic. Infection 2014, 42, 849–857.
  25. Sneller, M.C.; Blazkova, J.; Justement, J.S.; Shi, V.; Kennedy, B.D.; Gittens, K.; Tolstenko, J.; McCormack, G.; Whitehead, E.J.; Schneck, R.F.; et al. Combination Anti-HIV Antibodies Provide Sustained Virological Suppression. Nature 2022, 606, 375–381.
  26. Merigan, T.C. Treatment of AIDS with Combinations of Antiretroviral Agents. Am. J. Med. 1991, 90, 8S–17S.
  27. Nastri, B.M.; Zannella, C.; Folliero, V.; Rinaldi, L.; Restivo, L.; Stelitano, D.; Sperlongano, R.; Adinolfi, L.E.; Franci, G. Editorial-Role of Highly Active Antiretroviral Therapy (HAART) for the COVID-19 Treatment. Eur. Rev. Med. Pharm. Sci. 2020, 24, 11982–11984.
  28. Sanna, G.; Madeddu, S.; Murgia, G.; Serreli, G.; Begala, M.; Caboni, P.; Incani, A.; Franci, G.; Galdiero, M.; Giliberti, G. Potent and Selective Activity against Human Immunodeficiency Virus 1 (HIV-1) of Thymelaea Hirsuta Extracts. Viruses 2020, 12, E664.
  29. Scott, L.J. Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. Drugs 2020, 80, 61–72.
  30. Sarafianos, S.G.; Hughes, S.H.; Arnold, E. Designing Anti-AIDS Drugs Targeting the Major Mechanism of HIV-1 RT Resistance to Nucleoside Analog Drugs. Int. J. Biochem. Cell Biol. 2004, 36, 1706–1715.
  31. Voshavar, C. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges. Curr. Top. Med. Chem. 2019, 19, 1571–1598.
  32. Farady, C.J.; Craik, C.S. Mechanisms of Macromolecular Protease Inhibitors. ChemBiochem 2010, 11, 2341–2346.
  33. Ghosh, A.K.; Osswald, H.L.; Prato, G. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. J. Med. Chem. 2016, 59, 5172–5208.
  34. Brik, A.; Wong, C.-H. HIV-1 Protease: Mechanism and Drug Discovery. Org. Biomol. Chem. 2003, 1, 5–14.
  35. Anstett, K.; Brenner, B.; Mesplede, T.; Wainberg, M.A. HIV Drug Resistance against Strand Transfer Integrase Inhibitors. Retrovirology 2017, 14, 36.
  36. Delelis, O.; Carayon, K.; Saïb, A.; Deprez, E.; Mouscadet, J.-F. Integrase and Integration: Biochemical Activities of HIV-1 Integrase. Retrovirology 2008, 5, 114.
  37. Quashie, P.K.; Mesplède, T.; Wainberg, M.A. HIV Drug Resistance and the Advent of Integrase Inhibitors. Curr. Infect. Dis. Rep. 2013, 15, 85–100.
  38. Esté, J.A.; Telenti, A. HIV Entry Inhibitors. Lancet 2007, 370, 81–88.
  39. Pugach, P.; Ketas, T.J.; Michael, E.; Moore, J.P. Neutralizing Antibody and Anti-Retroviral Drug Sensitivities of HIV-1 Isolates Resistant to Small Molecule CCR5 Inhibitors. Virology 2008, 377, 401–407.
  40. Qian, K.; Morris-Natschke, S.L.; Lee, K.-H. HIV Entry Inhibitors and Their Potential in HIV Therapy. Med. Res. Rev. 2009, 29, 369–393.
  41. Dvory-Sobol, H.; Shaik, N.; Callebaut, C.; Rhee, M.S. Lenacapavir: A First-in-Class HIV-1 Capsid Inhibitor. Curr. Opin. HIV AIDS 2022, 17, 15–21.
  42. Diamond, T.L.; Ngo, W.; Xu, M.; Goh, S.L.; Rodriguez, S.; Lai, M.-T.; Asante-Appiah, E.; Grobler, J.A. Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Antimicrob. Agents Chemother. 2022, 66, e00133-22.
  43. Cane, P.A. Stability of Transmitted Drug-Resistant HIV-1 Species. Curr. Opin. Infect. Dis. 2005, 18, 537–542.
  44. Kitayimbwa, J.M.; Mugisha, J.Y.T.; Saenz, R.A. Estimation of the HIV-1 Backward Mutation Rate from Transmitted Drug-Resistant Strains. Popul. Biol. 2016, 112, 33–42.
  45. Abram, M.E.; Ferris, A.L.; Shao, W.; Alvord, W.G.; Hughes, S.H. Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication. J. Virol. 2010, 84, 9864–9878.
  46. Mansky, L.M. HIV Mutagenesis and the Evolution of Antiretroviral Drug Resistance. Drug Resist. Updat. 2002, 5, 219–223.
  47. Keele, B.F.; Giorgi, E.E.; Salazar-Gonzalez, J.F.; Decker, J.M.; Pham, K.T.; Salazar, M.G.; Sun, C.; Grayson, T.; Wang, S.; Li, H.; et al. Identification and Characterization of Transmitted and Early Founder Virus Envelopes in Primary HIV-1 Infection. Proc. Natl. Acad. Sci. USA 2008, 105, 7552–7557.
  48. Nasir, A.; Dimitrijevic, M.; Romero-Severson, E.; Leitner, T. Large Evolutionary Rate Heterogeneity among and within HIV-1 Subtypes and CRFs. Viruses 2021, 13, 1689.
  49. Levy, D.N.; Aldrovandi, G.M.; Kutsch, O.; Shaw, G.M. Dynamics of HIV-1 Recombination in Its Natural Target Cells. Proc. Natl. Acad. Sci. USA 2004, 101, 4204–4209.
  50. Hammer, S.M.; Saag, M.S.; Schechter, M.; Montaner, J.S.G.; Schooley, R.T.; Jacobsen, D.M.; Thompson, M.A.; Carpenter, C.C.J.; Fischl, M.A.; Gazzard, B.G.; et al. Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel. JAMA 2006, 296, 827–843.
  51. Coffin, J.M. HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy. Science 1995, 267, 483–489.
  52. Miller, R.L.; Ponte, R.; Jones, B.R.; Kinloch, N.N.; Omondi, F.H.; Jenabian, M.-A.; Dupuy, F.P.; Fromentin, R.; Brassard, P.; Mehraj, V.; et al. HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy. J. Virol. 2019, 93, e00755-19.
  53. Perelson, A.S.; Ribeiro, R.M. Modeling the Within-Host Dynamics of HIV Infection. BMC Biol. 2013, 11, 96.
  54. Tang, M.W.; Shafer, R.W. HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications. Drugs 2012, 72, e1–e25.
  55. Sun, Z.; Lan, Y.; Liang, S.; Wang, J.; Ni, M.; Zhang, X.; Yu, F.; Chen, M.; Zhang, H.; Yan, L.; et al. Prevalence of Doravirine Cross-Resistance in HIV-Infected Adults Who Failed First-Line ART in China, 2014-18. J. Antimicrob. Chemother. 2022, 77, 1119–1124.
  56. Novak, R.M.; Chen, L.; MacArthur, R.D.; Baxter, J.D.; Huppler Hullsiek, K.; Peng, G.; Xiang, Y.; Henely, C.; Schmetter, B.; Uy, J.; et al. Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV-Infected, Treatment-Naive Patients: Implications for Routine Resistance Screening before Initiation of Antiretroviral Therapy. Clin. Infect. Dis. 2005, 40, 468–474.
  57. Wensing, A.M.J.; van de Vijver, D.A.; Angarano, G.; Asjö, B.; Balotta, C.; Boeri, E.; Camacho, R.; Chaix, M.-L.; Costagliola, D.; De Luca, A.; et al. Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. J. Infect. Dis. 2005, 192, 958–966.
  58. Brenner, B.G.; Coutsinos, D. The K65R Mutation in HIV-1 Reverse Transcriptase: Genetic Barriers, Resistance Profile and Clinical Implications. HIV 2009, 3, 583–594.
  59. Ross, L.; Elion, R.; Lanier, R.; Dejesus, E.; Cohen, C.; Redfield, R.R.; Gathe, J.C.; Hsu, R.K.; Yau, L.; Paulsen, D.; et al. Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection in Subjects with Virologic Failure Receiving Once-Daily Abacavir/Lamivudine/Zidovudine and Tenofovir DF (Study COL40263). AIDS Res. Hum. Retrovir. 2009, 25, 665–672.
  60. Ren, J.; Stammers, D.K. Structural Basis for Drug Resistance Mechanisms for Non-Nucleoside Inhibitors of HIV Reverse Transcriptase. Virus Res. 2008, 134, 157–170.
  61. Antinori, A.; Zaccarelli, M.; Cingolani, A.; Forbici, F.; Rizzo, M.G.; Trotta, M.P.; Di Giambenedetto, S.; Narciso, P.; Ammassari, A.; Girardi, E.; et al. Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine Failure. AIDS Res. Hum. Retrovir. 2002, 18, 835–838.
  62. Ruxrungtham, K.; Pedro, R.J.; Latiff, G.H.; Conradie, F.; Domingo, P.; Lupo, S.; Pumpradit, W.; Vingerhoets, J.H.; Peeters, M.; Peeters, I.; et al. Impact of Reverse Transcriptase Resistance on the Efficacy of TMC125 (Etravirine) with Two Nucleoside Reverse Transcriptase Inhibitors in Protease Inhibitor-Naïve, Nonnucleoside Reverse Transcriptase Inhibitor-Experienced Patients: Study TMC125-C227. HIV Med. 2008, 9, 883–896.
  63. Varghese, V.; Shahriar, R.; Rhee, S.-Y.; Liu, T.; Simen, B.B.; Egholm, M.; Hanczaruk, B.; Blake, L.A.; Gharizadeh, B.; Babrzadeh, F.; et al. Minority Variants Associated with Transmitted and Acquired HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance: Implications for the Use of Second-Generation Nonnucleoside Reverse Transcriptase Inhibitors. J. Acquir. Immune Defic. Syndr. 2009, 52, 309–315.
  64. Lambert-Niclot, S.; Charpentier, C.; Storto, A.; Fofana, D.; Soulie, C.; Fourati, S.; Wirden, M.; Morand-Joubert, L.; Masquelier, B.; Flandre, P.; et al. Rilpivirine, Emtricitabine and Tenofovir Resistance in HIV-1-Infected Rilpivirine-Naive Patients Failing Antiretroviral Therapy. J. Antimicrob. Chemother. 2014, 69, 1086–1089.
  65. Melikian, G.L.; Rhee, S.-Y.; Varghese, V.; Porter, D.; White, K.; Taylor, J.; Towner, W.; Troia, P.; Burack, J.; Dejesus, E.; et al. Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Cross-Resistance: Implications for Preclinical Evaluation of Novel NNRTIs and Clinical Genotypic Resistance Testing. J. Antimicrob. Chemother. 2014, 69, 12–20.
  66. Brenner, B.; Turner, D.; Oliveira, M.; Moisi, D.; Detorio, M.; Carobene, M.; Marlink, R.G.; Schapiro, J.; Roger, M.; Wainberg, M.A. A V106M Mutation in HIV-1 Clade C Viruses Exposed to Efavirenz Confers Cross-Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors. AIDS 2003, 17, F1–F5.
  67. Ali, A.; Bandaranayake, R.M.; Cai, Y.; King, N.M.; Kolli, M.; Mittal, S.; Murzycki, J.F.; Nalam, M.N.L.; Nalivaika, E.A.; Özen, A.; et al. Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses 2010, 2, 2509–2535.
  68. Munerato, P.; Sucupira, M.C.; Oliveros, M.P.R.; Janini, L.M.; de Souza, D.F.; Pereira, A.A.; Inocencio, L.A.; Diaz, R.S. HIV Type 1 Antiretroviral Resistance Mutations in Subtypes B, C, and F in the City of São Paulo, Brazil. AIDS Res. Hum. Retrovir. 2010, 26, 265–273.
  69. Blanco, J.-L.; Varghese, V.; Rhee, S.-Y.; Gatell, J.M.; Shafer, R.W. HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications. J. Infect. Dis. 2011, 203, 1204–1214.
  70. Geretti, A.M.; Armenia, D.; Ceccherini-Silberstein, F. Emerging Patterns and Implications of HIV-1 Integrase Inhibitor Resistance. Curr. Opin. Infect. Dis. 2012, 25, 677–686.
  71. Clutter, D.S.; Jordan, M.R.; Bertagnolio, S.; Shafer, R.W. HIV-1 Drug Resistance and Resistance Testing. Infect. Genet. Evol. 2016, 46, 292–307.
  72. Cooper, D.A.; Steigbigel, R.T.; Gatell, J.M.; Rockstroh, J.K.; Katlama, C.; Yeni, P.; Lazzarin, A.; Clotet, B.; Kumar, P.N.; Eron, J.E.; et al. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. N. Engl. J. Med. 2008, 359, 355–365.
  73. Lennox, J.L.; DeJesus, E.; Lazzarin, A.; Pollard, R.B.; Madruga, J.V.R.; Berger, D.S.; Zhao, J.; Xu, X.; Williams-Diaz, A.; Rodgers, A.J.; et al. Safety and Efficacy of Raltegravir-Based versus Efavirenz-Based Combination Therapy in Treatment-Naive Patients with HIV-1 Infection: A Multicentre, Double-Blind Randomised Controlled Trial. Lancet 2009, 374, 796–806.
  74. Han, Y.-S.; Mesplède, T.; Wainberg, M.A. Differences among HIV-1 Subtypes in Drug Resistance against Integrase Inhibitors. Infect. Genet. Evol. 2016, 46, 286–291.
  75. Trkola, A.; Kuhmann, S.E.; Strizki, J.M.; Maxwell, E.; Ketas, T.; Morgan, T.; Pugach, P.; Xu, S.; Wojcik, L.; Tagat, J.; et al. HIV-1 Escape from a Small Molecule, CCR5-Specific Entry Inhibitor Does Not Involve CXCR4 Use. Proc. Natl. Acad. Sci. USA 2002, 99, 395–400.
  76. Moore, J.P.; Kuritzkes, D.R. A Pièce de Resistance: How HIV-1 Escapes Small Molecule CCR5 Inhibitors. Curr. Opin. HIV AIDS 2009, 4, 118–124.
  77. Lalezari, J.P.; Eron, J.J.; Carlson, M.; Cohen, C.; DeJesus, E.; Arduino, R.C.; Gallant, J.E.; Volberding, P.; Murphy, R.L.; Valentine, F.; et al. A Phase II Clinical Study of the Long-Term Safety and Antiviral Activity of Enfuvirtide-Based Antiretroviral Therapy. AIDS 2003, 17, 691–698.
  78. Cabrera, C.; Marfil, S.; García, E.; Martinez-Picado, J.; Bonjoch, A.; Bofill, M.; Moreno, S.; Ribera, E.; Domingo, P.; Clotet, B.; et al. Genetic Evolution of Gp41 Reveals a Highly Exclusive Relationship between Codons 36, 38 and 43 in Gp41 under Long-Term Enfuvirtide-Containing Salvage Regimen. AIDS 2006, 20, 2075–2080.
  79. Lu, J.; Deeks, S.G.; Hoh, R.; Beatty, G.; Kuritzkes, B.A.; Martin, J.N.; Kuritzkes, D.R. Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis. J. Acquir. Immune Defic. Syndr. 2006, 43, 60–64.
  80. Marcelin, A.-G.; Reynes, J.; Yerly, S.; Ktorza, N.; Segondy, M.; Piot, J.-C.; Delfraissy, J.-F.; Kaiser, L.; Perrin, L.; Katlama, C.; et al. Characterization of Genotypic Determinants in HR-1 and HR-2 Gp41 Domains in Individuals with Persistent HIV Viraemia under T-20. AIDS 2004, 18, 1340–1342.
  81. Menzo, S.; Castagna, A.; Monachetti, A.; Hasson, H.; Danise, A.; Carini, E.; Bagnarelli, P.; Lazzarin, A.; Clementi, M. Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment. Antimicrob. Agents Chemother. 2004, 48, 3253–3259.
  82. Sista, P.R.; Melby, T.; Davison, D.; Jin, L.; Mosier, S.; Mink, M.; Nelson, E.L.; DeMasi, R.; Cammack, N.; Salgo, M.P.; et al. Characterization of Determinants of Genotypic and Phenotypic Resistance to Enfuvirtide in Baseline and On-Treatment HIV-1 Isolates. AIDS 2004, 18, 1787–1794.
  83. Chang, L.; Zhao, J.; Guo, F.; Ji, H.; Zhang, L.; Jiang, X.; Wang, L. HIV-1 Gp41 Genetic Diversity and Enfuvirtide Resistance-Associated Mutations among Enfuvirtide-Naïve Patients in Southern China. Virus Res. 2021, 292, 198215.
  84. Kageyama, S.; Amolong Hinay, A.; Telan, E.F.O.; Samonte, G.M.J.; Leano, P.S.A.; Tsuneki-Tokunaga, A.; Kanai, K. Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines. J. Int. Assoc. Provid. AIDS Care 2019, 18, 2325958219856579.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback